Dimensional Fund Advisors LP Makes New Investment in Oruka Therapeutics, Inc. $ORKA

Dimensional Fund Advisors LP bought a new position in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 113,009 shares of the company's stock, valued at approximately $5,543,000. Dimensional Fund Advisors LP owned about 0.23% of Oruka Therapeutics as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of ORKA. Moody Aldrich Partners LLC bought a new stake in shares of Oruka Therapeutics during the 4th quarter worth $3,844,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Oruka Therapeutics in the 1st quarter worth about $1,811,000. SG Americas Securities LLC bought a new position in Oruka Therapeutics during the fourth quarter valued at about $251,000. Perceptive Advisors LLC grew its position in Oruka Therapeutics by 16.4% during the fourth quarter. Perceptive Advisors LLC now owns 1,476,501 shares of the company's stock valued at $44,753,000 after buying an additional 208,480 shares during the period. Finally, Jennison Associates LLC purchased a new stake in Oruka Therapeutics during the first quarter worth about $8,666,000. 56.44% of the stock is owned by institutional investors.

Oruka Therapeutics Stock Down 0.4%

NASDAQ ORKA opened at $104.68 on Wednesday. The company has a market cap of $6.31 billion, a PE ratio of -51.57 and a beta of -0.34. Oruka Therapeutics, Inc. has a 52 week low of $13.06 and a 52 week high of $107.55. The firm's 50-day simple moving average is $84.58 and its two-hundred day simple moving average is $61.25.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, equities research analysts anticipate that Oruka Therapeutics, Inc. will post -2.06 EPS for the current year.

Analyst Upgrades and Downgrades

ORKA has been the topic of several research reports. Barclays lifted their price objective on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the stock an "overweight" rating in a research report on Monday, April 27th. Guggenheim reissued a "buy" rating and set a $200.00 target price on shares of Oruka Therapeutics in a research report on Tuesday. Piper Sandler restated an "overweight" rating and set a $180.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. HC Wainwright reaffirmed a "buy" rating and issued a $120.00 price target on shares of Oruka Therapeutics in a report on Monday, August 3rd. Finally, UBS Group upped their price objective on Oruka Therapeutics from $100.00 to $130.00 and gave the company a "buy" rating in a research note on Wednesday, July 1st. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Oruka Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $134.30.

Insider Buying and Selling

In other news, insider Joana Goncalves sold 7,947 shares of the firm's stock in a transaction on Monday, June 15th. The stock was sold at an average price of $69.28, for a total value of $550,568.16. Following the completion of the transaction, the insider directly owned 32,718 shares of the company's stock, valued at $2,266,703.04. This trade represents a 19.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Arjun Agarwal sold 9,999 shares of the firm's stock in a transaction on Monday, July 13th. The stock was sold at an average price of $84.63, for a total value of $846,215.37. Following the completion of the transaction, the senior vice president directly owned 15,312 shares of the company's stock, valued at $1,295,854.56. The trade was a 39.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 188,406 shares of company stock worth $12,019,683. Insiders own 23.49% of the company's stock.

Key Stories Impacting Oruka Therapeutics

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Analyst support remains strong: Guggenheim reaffirmed its “buy” rating with a $200 price target, while Wedbush maintained “outperform” at $165 and BTIG reiterated “buy” at $151. These targets imply substantial potential appreciation from recent trading levels. Benzinga analyst rating reports Ticker Report analyst rating
• Positive Sentiment: Clinical pipeline advanced: EVERLAST-B fully enrolled ahead of schedule, with Week 16 psoriasis data expected in the fourth quarter of 2026. Oruka also expects EVERLAST-A Week 28 data by the end of the third quarter, plans to begin an ORKA-001 Phase 3 program in the first half of 2027, accelerated ORCA-SURGE data to the first quarter of 2027, and initiated the ORCA-SPLASH Phase 2 hidradenitis suppurativa trial.
• Positive Sentiment: Strong liquidity reduces near-term financing risk: Oruka reported $1.1 billion in cash, cash equivalents and marketable securities, which it expects will fund operations through a potential biologics license application for ORKA-001. ORKA-004 is also expected to enter clinical testing in the fourth quarter of 2026. Oruka second-quarter 2026 results and corporate update
• Neutral Sentiment: Short-interest data showed no meaningful positioning: Reported short interest was zero shares with a zero-day days-to-cover ratio, offering no indication of either short-covering support or heightened bearish pressure.
• Negative Sentiment: Quarterly results missed expectations: Oruka reported a second-quarter loss of $0.55 per share versus the $0.51 consensus estimate. Net loss widened to $41.2 million from $24.6 million a year earlier, while research and development expenses increased to $43.3 million from $24.1 million as clinical activity expanded. MarketBeat Oruka earnings report

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source